The survival curves for the TCGA-PRAD cohort (samples with missing clinical characteristics were removed) showed significant correlation between MBNL1-AS1 and the progression free interval (PFI) of the PC patients (Figure 2I) (p-value < 0.05). Here, MBNL1 is linked to prostate adenocarcinoma.